About Us
Working to give more patients the chance of a full and healthy life
Papyrus Therapeutics
About Us
Platform Company with Unique Approach to Tumor Suppression
– Leader in OPCML tumor suppression research, a promising alternative approach to cancer treatment
– Site of action is extracellular, circumventing intracellular delivery challenges seen in other tumor suppression therapies
Potential treatment for large patient populations across multiple tumor types
– Biomarkers indicate over 40% of solid tumors are potential targets, evidence of potential in underserved therapeutic areas including ovarian, colorectal, lung, breast, endometrial, renal and other solid tumors
Lead Candidate PYTX-004: Clinical data generation beginning in ~24 months
– First-in-class approach to direct tumor suppression via replacement of functional tumor suppressor protein
– PYTX-004 r-OPCML-Fc Fusion at the IND-enabling stage
Substantial Therapeutic Opportunities: Synergy with Current Therapies + Platform of Novel Tumor Suppressor Therapeutics
– Likelihood of synergy with RTK inhibitors, immunotherapy, cell therapy and current standards of care (SOC)
– IgLON domain shuffling platform enables potential for additional novel tumor suppression candidates